Considerations
Learn more about drug interactions with MIRAPEX
MIRAPEX has no predicted P450 interactions—an important consideration in patients on multiple medications.
Commonly prescribed medications that are metabolized by the P450 system include16,17*:
| Antibiotics: | ARBs: | Hormonal therapies: |
| Ciprofloxacin | Irbesartan | Estrogen |
| Clarithromycin | Losartan | |
| Erythromycin | Hypnotics: | |
| Benzodiazepines: | Eszopiclone | |
| Anticoagulants: | Alprazolam | |
| Warfarin | Midazolam | Inhibitors: |
| Gemfibrozil | ||
| Antidepressants: | Beta blockers: | |
| Escitalopram | Carvedilol | Miscellaneous: |
| Sertraline | Propranolol | Eplerenone |
| Methadone | ||
| Antifungals: | Calcium | Risperidone |
| Fluconazole | channel blockers: | Sildenafil |
| Ketoconazole | Diltiazem | |
| Felodipine | Proton | |
| Antipsychotics: | Verapamil | pump inhibitors: |
| Risperidone | Esomeprazole | |
| Thioridazine | Statins: | Lansoprazole |
| Atorvastatin | Pantoprazole | |
| Rosuvastatin | ||
| Simvastatin | ||
*Source: Prescribing Information for respective drugs. Please see respective Prescribing Information for more information about drug-drug interactions.
The potential for drug-drug interactions for each of these medications with MIRAPEX has not been tested. The likelihood of in vivo interactions cannot be predicted based upon in vitro findings. In the absence of comparative studies, no comparative efficacy is implied.
- In RLS clinical trials, 86% of patients on MIRAPEX had a concomitant diagnosis (metabolic, cardiovascular, musculoskeletal, nervous, or gastrointestinal)9
- MIRAPEX is not metabolized in the liver and is renally excreted
- In RLS patients with severe and moderate renal impairment (creatinine clearance 20-60 mL/min), the duration between titration steps should be increased to 14 days
- Cimetidine and other known inhibitors of the cationic transport system decrease the clearance of pramipexole
- Carbidopa/levodopa, selegiline, and probenecid do not influence the pharmacokinetics of pramipexole
- Amantadine may slightly decrease the clearance of pramipexole
- Dopamine antagonists may diminish the effectiveness of pramipexole
Learn more about Dosing and Administration information about MIRAPEX
Learn more about Dosing and Administration information about MIRAPEX
Discover the proven efficacy of MIRAPEX. Learn more
Discover the proven efficacy of MIRAPEX. Learn more
IMPORTANT SAFETY INFORMATION ABOUT MIRAPEX: MIRAPEX tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
MIRAPEX may cause patients to fall asleep without any warning, even while doing normal daily activities, such as driving. When taking MIRAPEX, hallucinations may occur and sometimes patients may feel dizzy, sweaty or nauseated upon standing up. The most common side effects in clinical trials for RLS were nausea, headache, and tiredness. Patients should talk with their doctor if they experience these problems.
Patients and caregivers should be informed that impulse control disorders/compulsive behaviors may occur while taking medicines, including pramipexole, to treat Parkinson's disease and RLS.
This information is intended for U.S. residents only. Products discussed herein may have different labeling in different countries.
Please see full Prescribing Information, including patient information.
